	US 12,454,551 B2
	Peptides as inhibitors of fibrotic matrix accumulation
Inaam Nakchbandi, Hirschberg (DE); Stefan Hamelmann, Heidelberg (DE); and Stephan Uebel, Wofratshausen (DE)
Assigned to Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Munich (DE)
Appl. No. 17/631,533
Filed by Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Munich (DE)
PCT Filed Jul. 28, 2020, PCT No. PCT/EP2020/071319 § 371(c)(1), (2) Date Jan. 31, 2022, PCT Pub. No. WO2021/018923, PCT Pub. Date Feb. 4, 2021.
Claims priority of application No. 19189468 (EP), filed on Jul. 31, 2019; and application No. 19194798 (EP), filed on Aug. 30, 2019.
Prior Publication US 2022/0267378 A1, Aug. 25, 2022
Int. Cl. A61K 38/00 (2006.01); A61P 1/16 (2006.01); A61P 11/00 (2006.01); A61P 35/00 (2006.01); C07K 7/06 (2006.01); C07K 7/52 (2006.01); C07K 7/64 (2006.01)

CPC C07K 7/52 (2013.01) [A61P 1/16 (2018.01); A61P 11/00 (2018.01); A61P 35/00 (2018.01); A61K 38/00 (2013.01)]

18 Claims

1. A peptide consisting of the general sequence Xa-Leu-Gln-Gly-Xb (SEQ ID NO: 1), wherein Xa is selected from Pro-Gly, Gly and Ac-Gly and Xb is selected from Glu and Glu-NH₂, and a pharmaceutically acceptable salt thereof.